Pharming Group N.V. (PHAR)
Pharming Group N.V. (PHAR) Stock Price, Analysis & Data
| Bid | 17.34 |
| Market Cap | 828.1M |
| Revenue (ttm) | 366.48M |
| Net Income (ttm) | 9.3M |
| Beta | 0.06 |
| EPS (ttm) | 0.14 |
| PE Ratio (ttm) | 83.57 |
| Forward PE | 38.11 |
| P/B (ttm) | 3.24 |
| P/S (ttm) | 2.26 |
| Earnings Date | Mar 17, 2022 |
| Ask | 12.17 |
| Volume | 35,381 |
| Avg. Volume (20D) | 11,619 |
| Open | 11.81 |
| Previous Close | 12.23 |
| Day's Range | 11.66 - 12.13 |
| 52-Week Range | 9.62 - 21.34 |
| Analyst | Strong Buy |
| Price Target | 37.5 (220.51%) |
| Dividends | n/a |
| Ex-Dividend Date | n/a |
About PHAR
Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company's lead product is RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule ...
Financial Performance
In 2025, Pharming's revenue was 376.13M, an increase of 26.56% compared to the previous year's 297.2M. Earnings were 2.85M, a decrease of -124.08%.
Financial StatementsAnalyst Forecast
According to 4 analyst ratings, the average rating for PHAR stock is "Strong Buy". The 12-month stock price forecast is 37.5, which is upside of 220.51% from the latest price.
Stock ForecastsEarnings Surprise
Analysts project revenue of ... Upgrade
